Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
pexelizumab in conjunction with CABG · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| pexelizumab in conjunction with CABG | DRUG | - |
Inclusion Criteria: * be at least 18 years of age; * have 2 or more of the following risk factors: • diabetes mellitus; • repeat CABG; • the need for urgent intervention, defined according to the ACC/AHA guidelines as being patients who are required to stay in the hospital due to medical factors...
Top 11 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Inclisiran, YMI024 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 4 | PHASE3 | Ziltivekimab |
| Viatris, Inc. | VTRS | 2 | PHASE3 | Selatogrel |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE3 | Zilebesiran |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE3 | Obicetrapib |
| GE Healthcare Technologies Inc. | GEHC | 3 | PHASE1 | Regadenoson |
| Humacyte, Inc. | HUMA | 1 | PHASE2 | CTEV |
| AstraZeneca PLC | AZN | 1 | - | Tezepelumab |
| Sanofi SA Sponsored ADR | SNY | 2 | - | alirocumab |
| Bayer | BAYRY | 1 | PHASE1 | Nurandociguat |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7763505 |
Pexelizumab was studied as an add-on treatment for patients with coronary artery disease undergoing coronary artery bypass grafting (CABG) with cardiopulmonary bypass. It was given in conjunction with CABG to reduce complications associated with the procedure. It is an investigational monoclonal antibody and is not an approved therapy.
Pexelizumab targets complement protein C5. It is a monoclonal antibody that inhibits C5, aiming to block the complement-mediated inflammatory response that can occur during cardiac surgery with cardiopulmonary bypass. By binding C5, it is designed to limit downstream inflammatory injury in patients undergoing CABG.
Pexelizumab was developed by AstraZeneca PLC, which trades under the ticker AZN. The company sponsored the Phase 3 PRIMO-CABG II trial evaluating pexelizumab in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass.
Pexelizumab was in Phase 3 clinical development for coronary artery disease in patients undergoing CABG. The Phase 3 PRIMO-CABG II trial has been completed. Pexelizumab is an investigational agent and is not approved for use.
Pexelizumab was evaluated in the Phase 3 PRIMO-CABG II trial, NCT00088179, titled Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass. The trial enrolled 4,000 participants across the United States, France, Germany, and the Netherlands and has been completed.